SEC Comment Letter for BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149) (BIVI) — May 7, 2019
BIOVIE INC. (BIVI, BIVIW) (CIK 0001580149)
Date: May 7, 2019 · CIK: 0001580149 · Accession: 0000000000-19-008162
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231136
Letter
May 7, 2019 Terren Peizer Chairman and Chief Executive Officer BioVie Inc. 11601 Wilshire Boulevard, Suite 1100 Los Angeles, CA 90025 Re:BioVie Inc. Registration Statement on Form S-1 Filed April 30, 2019 File No. 333-231136 Dear Mr. Peizer: We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Registration Statement on Form S-1 filed on April 30, 2019 Cover page 1.We note your disclosure of a recent sale price of your common stock on the OTCQB Marketplace. Please expand your disclosure to state the expected offering price per share or method by which the offering price will be determined. Refer to Instruction 2 to Item 501(b)(3) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameTerren Peizer Comapany NameBioVie Inc. May 7, 2019 Page 2 FirstName LastName Terren Peizer BioVie Inc. May 7, 2019 Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with any other questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Mitchell S. Nussbaum, Esq.
Show Raw Text
May 7, 2019
Terren Peizer
Chairman and Chief Executive Officer
BioVie Inc.
11601 Wilshire Boulevard, Suite 1100
Los Angeles, CA 90025
Re:BioVie Inc.
Registration Statement on Form S-1
Filed April 30, 2019
File No. 333-231136
Dear Mr. Peizer:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In our comment, we may ask you to provide us with information so
we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to the comment, we may have additional comments.
Registration Statement on Form S-1 filed on April 30, 2019
Cover page
1.We note your disclosure of a recent sale price of your common stock on the OTCQB
Marketplace. Please expand your disclosure to state the expected offering price per share
or method by which the offering price will be determined. Refer to Instruction 2 to Item
501(b)(3) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameTerren Peizer
Comapany NameBioVie Inc.
May 7, 2019 Page 2
FirstName LastName
Terren Peizer
BioVie Inc.
May 7, 2019
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Mitchell S. Nussbaum, Esq.